Vitamin market update: Incident in Swiss vitamin B3 production location
A recent incident at a Swiss vitamin B3 production facility has raised questions about potential supply disruptions. While the market has not yet reacted significantly, the event adds uncertainty to an already cautious sector. (Update week 22)
In partnership with Feed Additive Prices
Vitamin E 50%
There is still no update from BASF regarding the resumption of their vitamin business or the lifting of the force majeure. Despite multiple plant maintenance announcements from Chinese manufacturers scheduled for the coming period, the market remains relatively weak. Buyers have secured sufficient contracts for the near term, and it appears that enough suppliers are providing competitive pricing. This week has seen a slight decline in prices again across all regions, with Q2 already contracted and a portion of Q3 also secured.
Vitamin A 1000
In earlier communication, BASF indicated that vitamin A1000 production was planned to resume in April 2025, but as yet there is no sign of them returning to the market and/or lifting the force majeure. The overall trend remains the same, which means a step-by-step decline in market price in all major regions. Supply seems to be ample, and demand appears to be conservative. Q3 is still largely uncontracted.
Vitamin D3 500
The market remains relatively stable, though a slight decline in prices was observed last week in China, it is stable so far this week. Other regions continue to maintain elevated price levels due to ongoing tight supply conditions. A significant portion of the third-quarter contracts is already secured.
D-Calpan
Recent price adjustments by a leading supplier in China aimed at stimulating sales have yet to yield a response from the market. A market that continues to exhibit minimal trading activity across most regions, where prices remain relatively low. Currently, only a fraction of Q3 has been contracted, indicating a cautious outlook among buyers.
Vitamin B3
There is said to have been an incident at a vitamin B3 manufacturer in Switzerland, which has led to some disruption in the production process. No casualties reported, luckily. The market has not really reacted so far in terms of buying/selling activity or adjusting prices. Apart from that, the market shows signs of stabilisation following a recent decline in prices, prices which have remained relatively low. Buyers find themselves on the sidelines regarding any potential additional volumes and have a wait-and-see attitude. Q2 and a small portion of Q3 have been contracted.
